BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Redemplo (Plozasiran) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Redemplo (Plozasiran)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06822790-1043@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06822790)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Hypertriglyceridemia.\nStudy:
  Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglycer
 idemia\nEstimated primary completion: July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/plozasiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06822790
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880770-1043@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06880770)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: Study of Plozasiran in Adults With Severe Hypertriglyceridemia at 
 Risk of Acute Pancreatitis\nEstimated primary completion: March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/plozasiran#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06880770
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
